H1 2026 Unaudited Interim Report of the Krka Group and Krka

Novo mesto, July 2026

Living a healthy life.

CONTENTS

INTRODUCTION

The condensed consolidated financial statements of the Krka Group (hereinafter also the Group) and the condensed financial statements of Krka, d. d., Novo mesto (hereinafter also Krka, the Company, the controlling company, we, our, us) for H1 2026 and H1 2025 are unaudited. The financial statements for the year ended 31 December 2025 are audited. Krka has no authorised capital and made no conditional increase in share capital.

We promptly disclose all material changes to the information contained in the listing prospectus of Krka through the electronic information dissemination systems SEOnet of the Ljubljana Stock Exchange and ESPI of the Polish Financial Supervision Authority. Reports on business operations of the Krka Group and Krka, d. d. are available for viewing at www.krka.biz.

The Supervisory Board deliberated on the H1 2026 unaudited business report of the Krka Group and Krka at its regular meeting on 22 July 2026.

H1 2026 performance highlights

- Krka Group product and service sales totalled €1,113.8 million, of which product sales accounted for 98%.
- Product and service sales of the Krka Group increased by 7% year on year.
- We generated 94% of product and service sales outside Slovenia. Export accounted for 96% of total product sales.
- Region East Europe recorded the highest sales, accounting for 36.4% of total Krka Group sales, and was followed by Region Central Europe and Region West Europe.
- The Krka Group generated operating profit (EBIT) of €309.2 million, up 20% year on year. EBIT margin was 27.6%. EBITDA amounted to €357.5 million, up 18% year on year. EBITDA margin was 31.9%.
- Krka Group net profit totalled €260.2 million, up 5% year on year. Net profit margin was 23.2%.
- As at 30 June 2026, the Krka share traded at €250.50 on the Ljubljana Stock Exchange, up 23% on the year-end 2025. In the first half of 2026, we repurchased treasury shares in total of €19.0 million.
- We expanded our product portfolio with seven new products: six prescription pharmaceuticals and one animal health product.
- The Krka Group allocated €52.8 million to investments, up 29% year on year.
- At the end of June 2026, the Krka Group had 13,300 regularly employed persons on payroll, up 0.5% on year-end 2025. Total headcount, including agency workers, tallied 13,361 persons.

Krka and Krka Group highlights

€ thousand	Krka Group Jan–Jun 2026	Krka Group Jan–Jun 2025	Krka Group Index	Krka Jan–Jun 2026	Krka Jan–Jun 2025	Krka Index
Revenue	1,119,345	1,048,541	107	1,064,404	981,047	108
– Of which revenue from sales of products and services	1,113,781	1,045,775	107	871,335	839,558	104
Gross profit	682,260	607,385	112	660,227	578,250	114
Earnings before interest, tax, depreciation and amortisation (EBITDA)	357,453	303,254	118	357,179	297,429	120
Operating profit (EBIT)[1]	309,225	256,977	120	321,938	262,928	122
Profit before tax (EBT)	319,950	299,414	107	336,319	313,788	107
Net profit	260,170	246,680	105	273,842	257,861	106
R&D expenses	100,052	94,857	105	98,853	93,444	106
Investments	52,829	40,886	129	41,842	29,598	141

€ thousand	30 Jun 2026	31 Dec 2025	Index	30 Jun 2026	31 Dec 2025	Index
Non-current assets	1,085,060	1,059,759	102	1,074,286	1,058,622	101
Current assets	2,243,675	1,982,899	113	2,001,904	1,702,780	118
– Inventories	630,650	644,102	98	532,615	539,860	99
– Trade receivables	690,492	609,315	113	719,657	560,340	128
– Cash and cash equivalents	388,088	347,819	112	326,890	273,658	119
Equity	2,629,213	2,377,151	111	2,527,107	2,272,584	111
Non-current liabilities	166,978	165,213	101	135,226	132,921	102
Current liabilities	532,544	500,294	106	413,857	355,897	116
– Trade payables	150,667	124,654	121	195,978	160,231	122

Ratios	Jan–Jun 2026	Jan–Jun 2025	Jan–Jun 2026	Jan–Jun 2025
Gross profit margin	61.0%	57.9%	62.0%	58.9%
EBITDA margin	31.9%	28.9%	33.6%	30.3%
EBIT margin	27.6%	24.5%	30.2%	26.8%
EBT margin	28.6%	28.6%	31.6%	32.0%
Net profit margin (ROS)	23.2%	23.5%	25.7%	26.3%
Return on equity (ROE)[2]	20.8%	20.8%	22.8%	22.4%
Return on assets (ROA)[3]	16.3%	16.5%	18.8%	18.7%
Liabilities/Equity	0.266	0.254	0.217	0.199
R&D expenses/Revenue	8.9%	9.0%	9.3%	9.5%

Headcount	30 Jun 2026	31 Dec 2025	Index	30 Jun 2026	31 Dec 2025	Index
Balance at	13,300	13,236	100	7,766	7,733	100

Share information	Jan–Jun 2026	Jan–Jun 2025	Index
Total number of shares issued	32,793,448	32,793,448	100
Earnings per share (EPS) in €[4]	17.18	16.07	107
Closing price at end of period in €[5]	250.50	193.50	129
Price/Earnings ratio (P/E)	14.58	12.04	121
Book value in €[6]	80.17	76.45	105
Price/Book value (P/B)	3.12	2.53	123
Market capitalisation in € thousand (end of period)	8,214,759	6,345,532	129

[1] The difference between operating income and expenses
[2] Net profit, annualised/Average shareholders' equity in the period
[3] Net profit, annualised/Average total asset balance in the period
[4] Net profit attributable to majority equity holders of the Krka Group, annualised/Average number of shares issued in the period, excluding treasury shares
[5] Share price on the Ljubljana Stock Exchange
[6] Equity at the end of the period/Total number of shares issued

Krka ID card

Registered office Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Telephone +386 7 331 21 11
E-mail info@krka.biz
Website www.krka.biz
Core business Manufacture of pharmaceutical preparations
Business classification code 21.200
Year established 1954
Registration entry 1/00097/00, District Court of Novo mesto, Slovenia
Tax number 82646716
VAT registration number SI82646716
Company ID number 5043611000
Share capital €54,732,264.71
Total number of shares issued 32,793,448 ordinary registered no-par value shares, KRKG stock symbol. Krka shares have been listed on the Ljubljana Stock Exchange since 1997 under the KRKG stock symbol, and dual-listed on the Warsaw Stock Exchange since April 2012 under the KRK stock symbol.

Krka Group at a glance

The Krka Group consists of the controlling company, Krka, d. d., Novo mesto, a subsidiary in Slovenia, Terme Krka, d. o. o., Novo mesto, and 33 subsidiaries outside Slovenia.

The Krka Group develops, produces, markets, and sells human health products (prescription pharmaceuticals and non-prescription products), animal health products, and health resort and tourist services.

Production takes place at the controlling company in Slovenia and at subsidiaries in the Russian Federation, Poland, Croatia, and Germany. In addition to production, these subsidiaries, apart from Krka-Rus in the Russian Federation, deal with marketing and sales. In China, production takes place in leased production facilities. Other subsidiaries outside Slovenia market and/or sell Krka products, but do not have production capacities.

Terme Krka, d. o. o., Novo mesto provides health resort and tourist services and operates through the following business units: Terme Dolenjske Toplice; Terme Šmarješke Toplice; Hoteli Otočec; and Talaso Strunjan. Terme Krka is also the majority owner of Golf Grad Otočec, d. o. o.

In 2024, Krka and Laurus Labs Ltd. from India established a joint venture Krka Pharma Private Limited, in Hyderabad, India, where Krka holds a 51% stake. The Krka Group accounts for the investment in the joint venture under the equity method.

2026 Krka Group business plan

- We project revenue at €2,144 million, up 5% on 2025.
- The share of sales in markets outside Slovenia is estimated at 94%.
- We expect prescription pharmaceuticals to remain our leading product category, accounting for more than 80% of overall sales.
- We project net profit at €405 million.
- We plan to allocate over €140 million to investments, primarily for expanding and modernising production facilities and infrastructure.
- The total number of employees in Slovenia and abroad is projected to increase by 2%.

The 2026 business objectives derive from the *2026–2030 Krka Group Development Strategy* and are based on estimates, assessments, projections, and other available data. The Management Board believes these projections are reasonable. In the event of major changes in the business environment, such as price erosion, rising raw material prices, foreign exchange fluctuations for certain key currencies, or a decrease in demand for pharmaceutical products, actual operating results may deviate from the plan.

BUSINESS REPORT

Financial risks

Foreign exchange risk

Our key currency risk management policy remains to mitigate currency risk exposure by natural hedging. We also use financial instruments to a limited extent.

The Russian rouble continues to represent the largest Krka Group currency risk. Due to the limited availability of suitable financial hedging instruments in international markets, we employ natural hedging.

The Russian rouble appreciated by 3.7% against the euro during the first six months of 2026, while its average value against the euro was 6.7% higher year on year.

In the first half of 2026, we continued to hedge the US dollar using financial instruments. Unlike with other currencies, exposure to the US dollar arises from a surplus of liabilities over assets from regular business operations, or in other words, the currency position is short. Exposure to the US dollar arises primarily from the purchase of raw and other materials.

During the first six months of 2026, the US dollar strengthened by 3.1% against the euro, whereas its average value against the euro was 6.3% lower year on year.

Other currencies significant to our operations remained stable in the first half of 2026.

Net foreign exchange result, comprising net foreign exchange gains and losses and derivative income and expenses, amounted to €8.3 million. The Krka Group recorded net financial result of €10.7 million, which included foreign exchange result, interest income and expenses, and other financial income and expenses.

Credit risk

The Krka Group's main credit risk stems from trade receivables. The centralised credit control process at the Krka Group level includes all customers with credit limits exceeding €20,000. There were over 500 such clients at the end of the first half of 2026, accounting for more than 95% of total trade receivables. Credit control for small customers is decentralised within the sales network and remains under the constant supervision of the controlling company.

Our credit risk management policy remained unchanged in the first six months of the year. At the end of this period, more than 90% of Krka Group trade receivables were insured with a credit insurance company.

By the end of the first half of 2026, the total value of trade receivables denominated in euros increased by 13% from the beginning of the year. The maturity structure of receivables remained stable. The ratio of overdue receivables to total trade receivables remained within acceptable limits at the end of the first half of 2026.

Investor and share information

The Krka share price on the Ljubljana Stock Exchange increased by 23.4% over the first six months of 2026, and traded at €250.50 on 30 June 2026. The ownership structure remained stable, as there were no significant changes during this period. At the end of June 2026, Krka had 49,212 shareholders.

Shareholder structure (%)

	30 Jun 2026	31 Dec 2025
Slovenian retail investors	41.6	41.7
Slovenski državni holding (SDH, Slovenian Sovereign Holding) and the Republic of Slovenia	16.2	16.2
Kapitalska družba, d. d. (KD, Pension Fund Management) and Prvi pokojninski sklad (PPS, First Pension Fund)	10.8	10.8
Slovenian legal entities and institutional investors	5.9	5.8
Foreign investors	17.8	18.1
Treasury shares	7.7	7.4
Total	**100.0**	**100.0**

In the first half of 2026, Krka acquired 81,754 treasury shares, and held 2,516,581 treasury shares as at 30 June 2026, equivalent to 7.674% of its share capital.

Ten largest shareholders as at 30 June 2026

	Country	No. of shares	Equity stake (%)	Voting rights (%)
Kapitalska družba, d. d.	Slovenia	3,493,030	10.65	11.54
Slovenski državni holding, d. d.	Slovenia	2,949,876	9.00	9.74
Republic of Slovenia	Slovenia	2,366,424	7.22	7.82
OTP banka d.d.[1]	Croatia	1,493,617	4.55	4.93
Clearstream Banking SA[1]	Luxembourg	1,119,205	3.41	3.70
Erste Group Bank AG[1]	Austria	933,687	2.85	3.08
Luka Koper, d. d.	Slovenia	433,970	1.32	1.43
Raiffeisen Bank International AG[1]	Austria	325,409	0.99	1.07
Privredna banka Zagreb d. d.[1]	Croatia	309,930	0.95	1.02
Hrvatska poštanska banka d.d.[1]	Croatia	161,467	0.49	0.53
Total		**13,586,615**	**41.43**	**44.87**

[1] The shares are held in custody accounts with the above-listed banks and are owned by their clients.

Equity stakes and voting rights of Management and Supervisory Board members as at 30 June 2026

	No. of shares	Equity stake (%)	Voting rights (%)
Management Board members			
Jože Colarič	22,500	0.069	0.074
Aleš Rotar	13,915	0.042	0.046
Vinko Zupančič	120	0.000	0.000
Milena Kastelic	505	0.002	0.002
Total Management Board members	**37,040**	**0.113**	**0.122**
Supervisory Board members			
Julijana Kristl	230	0.001	0.001
Mojca Osolnik Videmšek	617	0.002	0.002
Tomaž Sever	500	0.001	0.001
Total Supervisory Board members	**1,347**	**0.004**	**0.004**
Total Management and Supervisory Board members	**38,387**	**0.117**	**0.126**

Krka share trading in H1 2026



As at 30 June 2026, Krka's market capitalisation on the Ljubljana Stock Exchange, including treasury shares, totalled €8.2 billion. The average daily trading volume of Krka shares during this period amounted to €1.0 million. Since April 2012, Krka shares have been dual-listed on the Warsaw Stock Exchange.

Krka Group performance analysis

Revenue

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Revenue from contracts with customers on sales of products and services	1,113,781	1,045,775	107
Revenue from contracts with customers on sales of materials, and other revenue	5,564	2,766	201
Total revenue	**1,119,345**	**1,048,541**	**107**
Other operating income	2,873	4,124	70
Financial income	16,921	57,334	30
Total income	**1,139,139**	**1,109,999**	**103**

Revenue by period



Expenses

€ thousand	Jan–Jun 2026	% of revenue	Jan–Jun 2025	% of revenue	Index
Cost of goods sold	437,085	39.0	441,156	42.1	99
Selling and distribution expenses	211,732	18.9	197,845	18.9	107
R&D expenses	100,052	8.9	94,857	9.0	105
General and administrative expenses	64,124	5.8	61,830	5.9	104
Total operating expenses	**812,993**	**72.6**	**795,688**	**75.9**	**102**
Financial expenses	6,196	0.6	14,897	1.4	42
Total expenses	**819,189**	**73.2**	**810,585**	**77.3**	**101**

Operating results

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Earnings before interest, tax, depreciation and amortisation (EBITDA)	357,453	303,254	118
Operating profit (EBIT)	309,225	256,977	120
Profit before tax (EBT)	319,950	299,414	107
Net profit	260,170	246,680	105

Net profit by period



Assets

€ thousand	30 Jun 2026	%	31 Dec 2025	%	Index
Non-current assets	**1,085,060**	**32.6**	**1,059,759**	**34.8**	**102**
Attributable to:					
– Property, plant and equipment	822,778	24.7	828,905	27.2	99
– Intangible assets	114,551	3.4	99,787	3.3	115
Current assets	**2,243,675**	**67.4**	**1,982,899**	**65.2**	**113**
Attributable to:					
– Inventories	630,650	18.9	644,102	21.2	98
– Trade receivables and other receivables	758,183	22.8	633,503	20.8	120
Total assets	**3,328,735**	**100.0**	**3,042,658**	**100.0**	**109**

Equity and liabilities

€ thousand	30 Jun 2026	%	31 Dec 2025	%	Index
Equity	**2,629,213**	**79.0**	**2,377,151**	**78.1**	**111**
Non-current liabilities	**166,978**	**5.0**	**165,213**	**5.4**	**101**
Attributable to:	137,315	4.1	135,188	4.4	102
– Provisions for post-employment benefits and other non-current employee benefits	128,921	3.9	126,324	4.2	102
– Provisions for lawsuits	8,112	0.2	8,245	0.3	98
– Other provisions	282	0.0	619	0.0	46
Current liabilities	**532,544**	**16.0**	**500,294**	**16.5**	**106**
– Trade payables	150,667	4.5	124,654	4.1	121
– Contract liabilities	181,375	5.5	191,984	6.3	94
– Other current liabilities	200,502	6.0	183,653	6.1	109
Total equity and liabilities	**3,328,735**	**100.0**	**3,042,658**	**100.0**	**109**

Performance ratios



Performance ratios are in line with the Krka Group's key strategic objectives.

Marketing and sales

In the first half of 2026, the Krka Group generated €1,119.3 million revenue, of which revenue from contracts with customers on sales of products and services totalled €1,113.8 million. Sales in markets outside Slovenia amounted to €1,045.5 million, accounting for 94% of total Krka Group sales.

Krka Group product and service sales by region

Sales increased in all sales regions and most markets, except in Region West Europe.

Product and service sales by region

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Region Slovenia	68,246	64,422	106
– % of total sales	*6.1*	*6.1*	
Region South-East Europe	159,406	148,196	108
– % of total sales	*14.3*	*14.2*	
Region East Europe	405,200	370,360	109
– % of total sales	*36.4*	*35.4*	
Region Central Europe	256,898	242,535	106
– % of total sales	*23.1*	*23.2*	
Region West Europe	181,863	187,021	97
– % of total sales	*16.3*	*17.9*	
Region Overseas Markets	42,168	33,241	127
– % of total sales	*3.8*	*3.2*	
Total	**1,113,781**	**1,045,775**	**107**

Region Slovenia

Product and service sales in Region Slovenia, our domestic market, totalled €68.2 million in the first half of 2026. Product sales were valued at €41.6 million, while services generated €26.6 million sales revenue.

Holding a 7.5% market share, we remained the leading pharmaceutical provider in Slovenia by sales value.

Products from our key therapeutic categories promoted in marketing campaigns contributed most substantially to sales, above all those for cardiovascular diseases; pain relief; the central nervous system; the gastrointestinal tract; and vitamins and minerals.

Among our prescription pharmaceuticals, the perindopril-based products from our cardiovascular portfolio stood out, particularly the two single-pill combinations Amlewel (perindopril/amlodipine/indapamide) and Amlessa (perindopril/amlodipine), which recorded the highest sales growth. Also, we bolstered brand awareness of our innovative single-pill combination Tolupind (telmisartan/indapamide). We further strengthened our leading market position and Krka's recognition in the antihypertensive segment with them. Sorvitimb (rosuvastatin/ezetimibe) and Sorvasta (rosuvastatin) recorded the highest sales growth of our statins. We also bolstered brand awareness of oral anticoagulants. Among them are two well-established medicines, Daxanlo (dabigatran) and Delianda (edoxaban) – the latter presented one of the highest sales increases – and the newly launched Xerdoxo (rivaroxaban), available in film-coated tablets in the 10 mg, 15 mg, and 20 mg strengths.

Our leading pain relievers were a NSAID Nalgesin Forte (naproxen), a non-opioid analgesic Algominal (metamizole), and an analgesic Daleron (paracetamol) 1000 mg.

We strengthened brand awareness of our antidepressant Dulsevia (duloxetine) and the antipsychotic Kventiax (quetiapine) from our central nervous system product group. We also increased the brand awareness of Vitamin D3 Krka 7000 IU (cholecalciferol), which is taken once per week.

Of our non-prescription products, we also enhanced the brand awareness of vitamins and minerals Magnezij Krka, our leading non-prescription product, followed by the analgesic Nalgesin S (naproxen). Our marketing and sales activities helped us bolster brand awareness of the sleep aid Noctiben Mea (doxylamine), the vitamin B-Complex, the proton pump inhibitor Nolpaza Control (pantoprazole), Flebaven (diosmin) for the treatment of symptoms of chronic venous insufficiency, Bilobil (ginkgo leaf extract) for enhancing cognitive performance, and Septabene (benzydamine/cetylpyridinium chloride), a product with antiseptic properties.

Sales of animal health products were driven by Fypryst Combo (fipronil/S-methoprene) for protection against fleas and ticks, and a wide-spectrum parasiticide Milprazon (milbemycin oxime/praziquantel). We expanded our animal health product range for pain relief by adding Robexera (robenacoxib) solution for injection to the list, which also includes our well-established Rycarfa (carprofen). We added Dehispot (praziquantel/emodepside) spot-on solution to our antiparasitic product portfolio.

Region South-East Europe

Product sales by market

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Romania	40,630	40,335	101
Croatia	28,036	26,508	106
Serbia	22,938	21,231	108
Bulgaria	18,432	17,160	107
North Macedonia	17,750	15,873	112
Bosnia and Herzegovina	16,528	14,800	112
Kosovo	6,048	5,362	113
Greece	4,268	2,296	186
Albania	2,449	2,311	106
Montenegro	2,327	2,319	100
Total	**159,406**	**148,196**	**108**

According to the latest data, we held a 7.2% market share by volume, and were the most successful provider of generic prescription pharmaceuticals in the pharmacy segment in **Romania**. Atoris (atorvastatin), Nolpaza (pantoprazole), Co-Prenessa (perindopril/indapamide), Co-Roswera (rosuvastatin/ezetimibe), Teotard (theophylline), and Roswera (rosuvastatin) generated the strongest sales. Nalgesin (naproxen) and Bilobil (ginkgo leaf extract) were our flagship non-prescription products. Antiparasitic products remained our best-selling animal health products, especially the Fypryst brand products and Selehold (selamectin).

In **Croatia**, we remained the second most successful generic pharmaceutical company by sales of prescription pharmaceuticals in the pharmacy segment. The leading prescription pharmaceuticals were Emanera (esomeprazole), Atoris (atorvastatin), and Co-Dalneva (perindopril/amlodipine/indapamide). We also recorded sales growth with our new products Xerdoxo (rivaroxaban), Delianda (edoxaban), Daxanlo (dabigatran), Valomindo (valsartan/indapamide), and Delxora (tramadol/dexketoprofen), as well as the tender product Meaxin (imatinib). Our latest launches were Xerdoxo, Delxora, and Bisonessa (bisoprolol/perindopril). Nalgesin (naproxen) and Septolete Duo (benzydamine/cetylpyridinium chloride) recorded the strongest sales of non-prescription products. The Fypryst brand products and Robexera (robenacoxib) generated the strongest sales of animal health products. Also, our newly launched Otomicol (miconazole/prednisolone/polymyxin) ear drops presented a sales increase.

Region East Europe

Product sales by market

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Russian Federation	251,182	218,567	115
Ukraine	53,094	49,697	107
Uzbekistan	27,607	31,663	87
Belarus	17,622	15,339	115
Mongolia	10,063	9,766	103
Kazakhstan	9,643	11,006	88
Moldova	9,464	9,133	104
Georgia	6,195	4,899	126
Azerbaijan	5,923	5,913	100
Armenia	5,567	5,004	111
Kyrgyzstan	4,574	4,751	96
Tajikistan	2,992	2,453	122
Turkmenistan	1,274	2,170	59
Total	**405,200**	**370,360**	**109**

In the **Russian Federation**, we recorded 15% sales growth in the first half of 2026, placing second among international providers of generic pharmaceuticals in the country according to the latest available data.

Prescription pharmaceuticals were the leading product group, accounting for 86% of overall country sales. Co-Perineva (perindopril/indapamide), Co-Dalneva (perindopril/amlodipine/indapamide), Duloxenta (duloxetine), Lorista (losartan), Roxera Plus (rosuvastatin/ezetimibe), Lorista H and Lorista HD (losartan/hydrochlorothiazide), Vamloset (valsartan/amlodipine), Valsacor (valsartan), Roxera (rosuvastatin), and Nolpaza (pantoprazole) were at the forefront. Roxera Plus (rosuvastatin/ezetimibe), Duloxenta (duloxetine), and Co-Perineva (perindopril/indapamide) presented the highest absolute growth. We were one of the leading suppliers of prescription pharmaceuticals in the pharmacy segment and the leading provider of generic cardiovascular prescription pharmaceuticals.

Sales of our non-prescription products were driven by Nalgesin (naproxen), Septolete Total (benzydamine/cetylpyridinium chloride), and Bilobil (ginkgo leaf extract). Selafort (selamectin), Milprazon (milbemycin oxime/praziquantel), and Cladaxxa (amoxicillin/clavulanic acid) generated the strongest sales of our animal health products.

Our Krka-Rus production plant supplied 72% of all Krka products sold in the Russian Federation.

As per the latest available data, we ranked second among foreign providers of medicines in **Ukraine**, with sales growth rate significantly outperforming market growth. Prescription pharmaceuticals remained the leading sales group, primarily owing to strong sales of Co-Prenessa (perindopril/indapamide), Co-Amlessa (perindopril/amlodipine/indapamide), Co-Valsacor (valsartan/hydrochlorothiazide), and Telmista H (telmisartan/hydrochlorothiazide). Non-prescription products that generated the highest sales were Nalgesin (naproxen), the Herbion brand products, and Septolete Total (benzydamine/cetylpyridinium chloride), while best-selling animal health products included Milprazon (milbemycin oxime/praziquantel) and Selafort (selamectin).

As per the latest available data, we remained the second largest provider of medicines by sales value in **Uzbekistan**. Our growth rate outstripped overall pharmaceutical market volume growth by 26%. Our paramount prescription pharmaceuticals were Nolpaza (pantoprazole), Amlessa (perindopril/amlodipine), and Valodip (valsartan/amlodipine), while Septolete Total (benzydamine/cetylpyridinium chloride) and Pikovit headed the non-prescription product list.

Region Central Europe

Product sales by market

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Poland	128,196	122,047	105
Czechia	36,717	34,449	107
Hungary	31,039	28,008	111
Slovakia	23,148	22,226	104
Lithuania	20,045	19,488	103
Latvia	11,424	10,408	110
Estonia	6,329	5,908	107
Total	**256,898**	**242,535**	**106**

Poland, where we recorded 5% growth, remained our second largest individual market. Based on the latest data, we remained the fifth largest provider of generic medicines in the country. Sales were driven by prescription pharmaceuticals, most notably Atoris (atorvastatin), Roswera (rosuvastatin), Doreta (tramadol/paracetamol), Valsacor (valsartan), Co-Valsacor (valsartan/hydrochlorothiazide), and Coroswera (rosuvastatin/ezetimibe). Of other prescription pharmaceuticals, Emanera (esomeprazole), Dulsevia (duloxetine), and Asentra (sertraline) also generated strong sales. The leading non-prescription products remained Septanazal (xylometazoline/dexpanthenol) and the Septolete brand products. Best-selling animal health products were Milprazon (milbemycin oxime/praziquantel), Enroxil (enrofloxacin), and Cladaxxa (amoxicillin/clavulanic acid).

In **Czechia**, our second largest regional market, we recorded 7% year-on-year growth. As per latest data, we remained the fifth largest provider of generic medicines in the country. Sales were driven in particular by prescription pharmaceuticals, most notably Sorvasta (rosuvastatin), Atoris (atorvastatin), Pragiola (pregabalin), Nolpaza (pantoprazole), Elicea (escitalopram), and Lexaurin (bromazepam). Nalgesin S (naproxen) and Nolpaza (pantoprazole) were our paramount non-prescription products, while the Fypryst and Dehinel brand products remained key animal health products.

In **Hungary**, our third largest regional market by sales, we recorded 11% year-on-year sales growth, ranking sixth among providers of generic pharmaceuticals. Prescription pharmaceuticals generated the highest sales, in particular Dulsevia (duloxetine), Co-Prenessa (perindopril/indapamide), Doreta (tramadol/paracetamol), Emozul (esomeprazole), Roxera (rosuvastatin), Kventiax (quetiapine), Zyllt (clopidogrel), and Roxera Plus (rosuvastatin/ezetimibe). Our best-selling non-prescription products were Septanazal (xylometazoline/dexpanthenol), Bilobil (ginkgo leaf extract), and Nolpaza (pantoprazole). Milprazon (milbemycin oxime/praziquantel) and Enroxil (enrofloxacin) were the leading animal health products.

We maintained the fourth place among providers of generic medicines in **Slovakia**. Year on year, growth was 4%. Prescription pharmaceuticals generated the highest sales, in particular Amlessa (perindopril/amlodipine), Co-Prenessa (perindopril/indapamide), Atoris (atorvastatin), Co-Amlessa (perindopril/amlodipine/indapamide), Nolpaza (pantoprazole), Prenessa (perindopril), and Kventiax (quetiapine). Nalgesin S (naproxen), Flebaven (diosmin), and Nolpaza (pantoprazole) recorded the highest sales of non-prescription products, while the Fypryst and Dehinel brand products and Enroxil (enrofloxacin) sold best of animal health products.

Region West Europe

Product sales by market

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Germany	47,115	46,916	100
Nordic countries[1]	36,315	37,113	98
Portugal	19,734	18,936	104
Italy	13,042	15,287	85
Spain	11,450	12,390	92
United Kingdom	10,769	11,059	97
France	9,790	11,024	89
Ireland	7,472	7,054	106
Netherlands	6,917	7,305	95
Belgium	6,734	8,977	75
Austria	6,566	6,602	99
Other European countries	5,963	4,359	137
Total	**181,863**	**187,021**	**97**

[1] Denmark, Finland, Iceland, Norway, and Sweden

We recorded a slight year-on-year sales increase in **Germany**, which remained our largest regional market. Sales were driven by medicines for the treatment of cardiovascular diseases and the central nervous system, followed by oncology agents, and anti-infectives for systemic use. Agents containing candesartan, atorvastatin, valsartan, and ramipril generated the strongest sales. We remained the leading supplier of the tramadol/paracetamol single-pill combinations and cyproterone-based medicines. We successfully placed on the market a single-pill combination of tramadol and dexketoprofen and maintained our position among the leading providers of ticagrelor-based products. We remained the leading provider of the innovative single-pill combination of valsartan and indapamide. Sales of our non-prescription products increased by 21%, primarily on the back of the benzydamine/cetylpyridinium chloride combination products marketed under the Septolete brand. We increased sales of our animal health products by 6%. The milbemycin/praziquantel tablet wormer recorded the strongest sales.

Region Overseas Markets

Product sales by market

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Far East and Africa	22,109	17,867	124
China	9,964	5,610	178
Middle East	8,109	8,751	93
Americas	1,987	1,013	196
Total	**42,168**	**33,241**	**127**

In the first six months of 2026, our Region Overseas Market increased year-on-year sales by 27%. Sales increased in all countries except in the **Middle East** markets.

Product and service sales by group

Product and service sales by group

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Prescription pharmaceuticals	943,943	878,260	107
– % of total sales	*84.7*	*84.0*	
Non-prescription products	76,432	77,916	98
– % of total sales	*6.9*	*7.4*	
Animal health products	66,840	63,422	105
– % of total sales	*6.0*	*6.1*	
Health resort and tourist services	26,566	26,177	101
– % of total sales	*2.4*	*2.5*	
Total	**1,113,781**	**1,045,775**	**107**

Prescription pharmaceuticals

Sales of our prescription pharmaceuticals increased in Region Slovenia and Region East Europe (up 12% each), Region South-East Europe (up 9%), Region Central Europe (up 7%), and Region Overseas Markets (up 23%), while they declined in Region West Europe (down 4%).

As of our four largest markets, year-on-year sales increased in the Russian Federation (up 18%), Ukraine (up 8%), and Poland (up 5%), while they decreased in Germany (down 1%). We also recorded sales growth in other major markets: in Hungary (up 14%), Slovenia (up 12%), Czechia (up 9%), Serbia and Croatia (up 7% each), Slovakia (up 5%), and Romania (up 4%).

The top ten prescription pharmaceuticals by sales were product groups containing perindopril (Prenessa*, Co-Prenessa*, Amlessa*, Co-Amlessa*, Bi-Prenessa*, Pixoroso*, Roxiper*, Roxampex*); valsartan (Valsacor*, Co-Valsacor*, Wamlox*, Valtricom*, Valomindo*, Valarox*); rosuvastatin (Roswera*, Co-Roswera*); atorvastatin (Atoris, Co-Atoris*); pantoprazole (Nolpaza*); losartan (Lorista*, Lorista H*, Lorista HD*, Tenloris*); telmisartan (Tolura*, Tolucombi*, Telassmo*, Tolutris*, Tolurindo*); duloxetine (Dulsevia*); esomeprazole (Emanera*), and tramadol (Tadol*, Doreta*, Delanxara*).

Product groups containing rosuvastatin, perindopril, telmisartan, atorvastatin, and duloxetine contributed the most to sales growth.

We extended our product portfolio with newly launched medicines: an immunosuppressant for the treatment of psoriasis and psoriatic arthritis Apremilast Krka in Germany, the Nordic countries, the United Kingdom, Belgium, France, Slovakia, Ireland, and the Netherlands; the single-pill combination antihypertensive Bi-Prenessa* (perindopril/ bisoprolol) in the Russian Federation, Latvia, Bulgaria, Slovakia, and Croatia; and the single-pill combination analgesic Delanxara* (tramadol/dexketoprofen) in Poland, Portugal, Croatia, Hungary, Czechia, Germany, Latvia, Estonia, and Moldova.

Non-prescription products

Year-on-year sales of non-prescription products more than doubled in Region Overseas Markets, while they remained at the last year's level in Region Slovenia. Sales decreased in all other sales regions, in Region Central Europe (down 2%), Region South-East Europe (down 4%), Region East Europe (down 5%), and Region West Europe (down 7%). A mild flu and cold season in the first half of the year impacted our sales of seasonal products across all regions.

Nalgesin* (naproxen) and products sold under the Septolete*, Septanazal, Bilobil*, and Herbion* brands generated the highest sales.

Animal health products

Sales of animal health products increased in Region West Europe (up 14%), Region Slovenia (up 8%), Region Central Europe (up 4%), Region South-East Europe (up 3%), and Region East Europe (up 1%).

The combination of milbemycin oxime and praziquantel (Milprazon*), fipronil (Fypryst*, Fypryst Combo*), selamectin (Selehold*), the combination of amoxicillin and clavulanic acid (Cladaxxa*), and the combination of pyrantel and praziquantel (Dehinel*, Dehinel Plus*) generated the strongest sales.

We launched Dehispot* (praziquantel/emodepside) spot-on solution for cats, a completely new addition to our portfolio of antiparasitics, in Germany, the United Kingdom, France, Slovenia, Poland, Czechia, Portugal, Slovakia, Hungary, the Nordic countries, Lithuania, Latvia, Bulgaria, and Ukraine.

Health resort and tourist services

Terme Krka recorded over 162,000 overnight stays in the first half of 2026. All business units recorded high occupancy rates. Talaso Strunjan recorded nearly 59,000 overnight stays, the highest of our resorts, followed by Terme Šmarješke Toplice with 57,000 and Hoteli Otočec with over 8,000. With Hotel Vital closed for extensive reconstruction, Terme Dolenjske Toplice recorded 39,000 overnight stays.

Products marketed under different product brand names or the Krka trademark in individual markets are marked with asterisk (*).

Research and development

In the first half of 2026, we expanded our product range with seven new products: six new prescription medicines and one animal health product. We finalised over 300 registration procedures for new and already established products in several markets.

Prescription pharmaceuticals

In the first half of 2026, we completed registration procedures for six new prescription pharmaceuticals and obtained marketing authorisations for our established products in new markets.

We obtained first marketing authorisations for two single-pill antidiabetic combinations, **Mempoglyn*** (empagliflozin/metformin) and **Lymerexo*** (linagliptin/metformin). The two agents in film-coated tablets combine two active substances with synergistic modes of action, providing a modern and comprehensive approach to the treatment of type 2 diabetes, and allowing for patient-tailored therapies. We expanded our cardiovascular portfolio by obtaining marketing authorisations for **Co-Pitavador*** (pitavastatin/ezetimibe), a single-pill combination for the treatment of advanced hyperlipidaemia. Marketing authorisations were also granted for a new formulation of **Dulsevia***/**Loxentia** (duloxetine) hard gastro-resistant capsules. This established medicine is used in several therapeutic areas, but primarily to treat central nervous system disorders such as depression and anxiety, and to relieve pain caused by diabetic peripheral neuropathy in adults. We obtained marketing authorisations for two new products in China, **bisoprolol/amlodipine** combination tablets and **edoxaban** film-coated tablets. This further strengthened our presence in the treatment of chronic non-communicable diseases.

Our established products were granted new marketing authorisations in additional markets. Of these, we should mention two agents registered in the European Union: **Roxera Plus** (rosuvastatin/ezetimibe), a single-pill combination for the treatment of patients with progressive hyperlipidaemia, and **naproxen**, an analgesic. The two medicines are available in film-coated tablets. In eastern European countries, additional approvals were granted for the single-pill combination **Nalgesin Duo** (naproxen/paracetamol) film-coated tablets used to treat mild to moderate pain, antidiabetic agents in film-coated tablets, **Dapafors** (dapagliflozin) and **Dapafors Met** (dapagliflozin/metformin), and the single-pill combination **Valsacor INDA** (valsartan/indapamide) modified-release tablets used for lowering high blood pressure. We also obtained marketing authorisations for a single-pill combination, **Atoris Plus** (atorvastatin/ezetimibe) film-coated tablets indicated for the treatment of various types of hyperlipidaemia. In markets of south-eastern Europe, we obtained marketing authorisations for two single-pill antidiabetic agents in film-coated tablets, **Mexdagry** (dapagliflozin/metformin) and **Dagraduo** (dapagliflozin/sitagliptin), and for a single-pill combination in modified-release tablets used to treat high blood pressure, **Tolurindo** (telmisartan/indapamide). Additional marketing authorisations were granted for two antithrombotic agents, **Daxanlo** (dabigatran) capsules and **Aboxoma** (apixaban) film-coated tablets. We were also granted several new marketing authorisations for our overseas markets. We obtained approvals for **Roswera** (rosuvastatin) film-coated tablets used to treat hyperlipidaemia and **Prenewel** (perindopril/indapamide) tablets indicated for the treatment of hypertension.

Non-prescription products

We extended our portfolio of consumer health products with obtaining marketing authorisations for already established brands in additional markets. Among them are **Septolete Total Lemon-and-Ginger Flavoured Lozenges** (benzydamine/cetylpyridinium chloride) and **Septolete Total Cola-Flavoured Lozenges** for relieving pain and inflammation in the oral cavity and throat, and **Herbion Iceland Moss** lozenges for relieving irritation of the mucosa in the throat and mouth, as well as the associated dry cough. Also, **Herbion Ivy Syrup** indicated to help expectoration was approved in additional market.

Animal health products

We expanded the range of animal health products for companion animals with marketing authorisations for our new product **Robexera** (robenacoxib) chewable tablets for cats, registered as **Rogiola** in certain countries. It is indicated for the control of pain and inflammation associated with musculoskeletal diseases and for the relief of moderate pain and inflammation after surgery.

New marketing authorisations were granted to already established animal health products in additional markets. Among them are **Dehispot** (praziquantel/emodepside) spot-on solution indicated for the treatment and prevention of internal parasitic infections in cats and **Marinia** (maropitant) solution for injection, registered as **Arocenia** in certain countries, which is used to treat and prevent nausea and vomiting in dogs and cats. Also, we received new approvals for our companion animal products in overseas markets.

Products marketed under different product brand names or the Krka trademark in individual markets are marked with asterisk (*).

Investments

In the first half of 2026, the Krka Group allocated €52.8 million to investments, of which €41.8 million to the controlling company.

The upgrades at the Notol plant in Novo mesto, Slovenia, are intended to ensure reliable operations over the next 20 years. We plan to upscale the production capacity by building an extension to the solid dosage production plant. We intend to increase the production capacities by installing additional equipment at Notol 2, another production plant in Novo mesto.

We completed the investment in additional capacities for tabletting mixture preparation, granulation, and logistics at the Solid Dosage Products plant in Novo mesto, Slovenia, and embarked on a new project to increase production output.

We installed a new suspension inspection line and finished building an extension for a new production line for sterile solutions at the Sterile Products Department in Novo mesto, Slovenia, to significantly enhance production volumes.

Work is in progress at the Bršljin Department in Novo mesto, Slovenia, to increase the production and packaging capacities for products for veterinary use. We also expect to boost the capacity for packaging tablets for use in veterinary medicine and spot-on solutions in the existing facility.

We increased the production capacity at the Ljutomer plant in Slovenia. Construction of an automated high-bay warehouse and an expansion of the plant are under way.

We completed construction of the technically and technologically advanced waste water treatment plant in Krško, Slovenia. Pre-treatment has been in operation since September 2025. We also put to use the remaining technological phases of the biological treatment, and the plant is currently in trial operation.

We are currently increasing production capacity at the production and distribution centre in Jastrebarsko, Croatia.

In China, we set up product manufacturing to support animal health programme. A filling-and-packaging line was installed and qualified.

Construction of research and production facilities for oncology products and solid dosage forms is underway at Krka Pharma Private Limited, a joint venture in Hyderabad, India.

Employees

At the end of June 2026, the Krka Group employed 13,300 persons, of whom 5,565 or 42% worked outside Slovenia. Of all Krka Group employees, 47.5% held at least a university degree, 206 held doctoral degrees.

Krka Group employees by education

	30 Jun 2026		31 Dec 2025	
	Headcount	%	**Headcount**	%
PhD	206	1.5%	202	1.5%
Master of Science	379	2.9%	392	3.0%
University degree	5,737	43.1%	5,697	43.0%
Higher professional education	2,319	17.4%	2,265	17.1%
Vocational college education	372	2.8%	369	2.8%
Secondary school education	3,135	23.6%	3,161	23.9%
Other	1,152	8.7%	1,150	8.7%
Total	**13,300**	**100.0%**	**13,236**	**100.0%**

We continue to attract new talented employees by awarding scholarships. At the end of June, Krka had 66 scholarship holders, primarily pharmacy and chemistry students. We also offer scholarships to exceptional students from other fields that might be of interest to us. Our personnel development and succession planning system ensure that key professional and managerial positions are occupied by Krka Group employees.

We also invest in development and skills of our personnel. Employees in Slovenia and abroad acquire additional knowledge through training programmes, covering their respective professional fields as well as quality assurance, leadership, information technology, and personal development. They also participate in foreign language courses. We deliver most educational programmes in-house and tailor them to employee needs, technological processes, market situations, and development requirements of the Krka Group. We update the programmes regularly and introduce new forms of education adapted to the contemporary approaches to work.

In the first half of 2026, we offered educational support to 112 employees enrolled in part-time studies, including 25 at the postgraduate level.

Krka is also included in the national vocational qualification (NVQ) system. Between 2004 and the end of June 2026, we awarded 2,189 NVQ certificates to Krka employees for four vocational qualifications. At the end of June, 63 Krka employees were included in obtaining a national vocational qualification.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF THE KRKA GROUP, WITH NOTES

Consolidated statement of financial position of the Krka Group

€ thousand	30 Jun 2026	31 Dec 2025	Index
Assets			
Property, plant and equipment	822,778	828,905	99
Intangible assets	114,551	99,787	115
Investments in joint ventures	14,960	15,213	98
Loans	31,140	25,115	124
Investments	19,338	20,060	96
Deferred tax assets	81,059	69,469	117
Other non-current assets	1,234	1,210	102
Total non-current assets	**1,085,060**	**1,059,759**	**102**
Inventories	630,650	644,102	98
Contract assets	630	602	105
Trade receivables	690,492	609,315	113
Other receivables	67,691	24,188	280
Loans	124,041	99,585	125
Investments	342,083	257,288	133
Cash and cash equivalents	388,088	347,819	112
Total current assets	**2,243,675**	**1,982,899**	**113**
Total assets	**3,328,735**	**3,042,658**	**109**
Equity			
Share capital	54,732	54,732	100
Treasury shares	-244,054	-225,047	108
Reserves	277,496	249,022	111
Retained earnings	2,521,448	2,279,945	111
Total equity attributable to the holders of the controlling company	**2,609,622**	**2,358,652**	**111**
Non-controlling interests	19,591	18,499	106
Total equity	**2,629,213**	**2,377,151**	**111**
Liabilities			
Provisions	137,315	135,188	102
Deferred income	5,229	5,351	98
Lease liabilities	13,868	14,011	99
Deferred tax liabilities	10,566	10,663	99
Total non-current liabilities	**166,978**	**165,213**	**101**
Provisions	27,820	27,494	101
Trade payables	150,667	124,654	121
Borrowings	0	3	0
Lease liabilities	4,563	4,347	105
Income tax payables	32,515	33,263	98
Contract liabilities	181,375	191,984	94
Other current liabilities	135,604	118,549	114
Total current liabilities	**532,544**	**500,294**	**106**
Total liabilities	**699,522**	**665,507**	**105**
Total equity and liabilities	**3,328,735**	**3,042,658**	**109**

Consolidated income statement of the Krka Group

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Revenue	**1,119,345**	**1,048,541**	**107**
– Revenue from contracts with customers	1,117,217	1,046,707	107
– Other revenue	2,128	1,834	116
Cost of goods sold	-437,085	-441,156	99
Gross profit	**682,260**	**607,385**	**112**
Other operating income	2,873	4,124	70
Selling and distribution expenses	-211,732	-197,845	107
– Whereof net impairments and write-offs of receivables	-130	-3,106	4
R&D expenses	-100,052	-94,857	105
General and administrative expenses	-64,124	-61,830	104
Operating profit	**309,225**	**256,977**	**120**
Financial income	16,921	57,334	30
Financial expenses	-6,196	-14,897	42
Net financial result	**10,725**	**42,437**	**25**
Profit before tax	**319,950**	**299,414**	**107**
Income tax expense	-59,780	-52,734	113
Net profit	**260,170**	**246,680**	**105**
Attributable to:			
– Equity holders of the controlling company	260,259	245,844	106
– Non-controlling interests	-89	836	
Basic earnings per share[1] (€)	**8.59**	**8.04**	**107**
Diluted earnings per share[2] (€)	**8.59**	**8.04**	**107**

[1] Net profit/Average number of shares issued in the period, excluding treasury shares
[2] All shares issued by the company are ordinary shares, hence the diluted earnings per share ratio equalled basic earnings per share.

Consolidated statement of other comprehensive income of the Krka Group

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Net profit	**260,170**	**246,680**	**105**
Other comprehensive income for the period			
Other comprehensive income reclassified to profit or loss at a future date			
Translation reserve	11,211	48,062	23
Net other comprehensive income reclassified to profit or loss at a future date	**11,211**	**48,062**	**23**
Other comprehensive income that will not be reclassified to profit or loss at a future date			
Change in fair value of financial assets	-721	-1,793	40
Deferred tax effect	158	394	40
Net other comprehensive income that will not be reclassified to profit or loss at a future date	**-563**	**-1,399**	**40**
Total other comprehensive income for the period (net of tax)	**10,648**	**46,663**	**23**
Total comprehensive income for the period (net of tax)	**270,818**	**293,343**	**92**
Attributable to:			
– Equity holders of the controlling company	269,726	294,453	92
– Non-controlling interests	1,092	-1,110	

Consolidated statement of changes in equity of the Krka Group

€ thousand	Share capital	Treasury shares	Reserves: Reserves for treasury shares	Reserves: Share premium	Reserves: Legal reserves	Reserves: Statutory reserves	Reserves: Fair value reserve	Reserves: Translation reserve	Retained earnings: Other profit reserves	Retained earnings: Retained earnings from previous periods	Retained earnings: Profit for the period	Total equity attributable to the holders of the controlling company	Non-controlling interests	Total equity
Balance at 1 Jan 2026	**54,732**	**-225,047**	**225,047**	**105,897**	**14,990**	**30,000**	**-6,579**	**-120,333**	**1,679,151**	**259,114**	**341,680**	**2,358,652**	**18,499**	**2,377,151**
Net profit	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**260,259**	**260,259**	**-89**	**260,170**
Total other comprehensive income for the period (net of tax)	**0**	**0**	**0**	**0**	**0**	**0**	**-571**	**10,038**	**0**	**0**	**0**	**9,467**	**1,181**	**10,648**
Total comprehensive income for the period (net of tax)	**0**	**0**	**0**	**0**	**0**	**0**	**-571**	**10,038**	**0**	**0**	**260,259**	**269,726**	**1,092**	**270,818**
Transactions with owners, recognised in equity														
Transfer of previous periods' profit to retained earnings	0	0	0	0	0	0	0	0	0	341,680	-341,680	0	0	0
Repurchase of treasury shares	0	-19,007	0	0	0	0	0	0	0	0	0	-19,007	0	-19,007
Formation of reserves for treasury shares	0	0	19,007	0	0	0	0	0	0	0	-19,007	0	0	0
Dividends paid	0	0	0	0	0	0	0	0	0	251	0	251	0	251
Total transactions with owners, recognised in equity	**0**	**-19,007**	**19,007**	**0**	**0**	**0**	**0**	**0**	**0**	**341,931**	**-360,687**	**-18,756**	**0**	**-18,756**
Balance at 30 Jun 2026	**54,732**	**-244,054**	**244,054**	**105,897**	**14,990**	**30,000**	**-7,150**	**-110,295**	**1,679,151**	**601,045**	**241,252**	**2,609,622**	**19,591**	**2,629,213**

€ thousand	Share capital	Treasury shares	Reserves: Reserves for treasury shares	Reserves: Share premium	Reserves: Legal reserves	Reserves: Statutory reserves	Reserves: Fair value reserve	Reserves: Translation reserve	Retained earnings: Other profit reserves	Retained earnings: Retained earnings from previous periods	Retained earnings: Profit for the period	Total equity attributable to the holders of the controlling company	Non-controlling interests	Total equity
Balance at 1 Jan 2025	**54,732**	**-163,491**	**163,491**	**105,897**	**14,990**	**30,000**	**-11,362**	**-166,701**	**1,620,098**	**238,545**	**331,984**	**2,218,183**	**19,601**	**2,237,784**
Net profit	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**245,844**	**245,844**	**836**	**246,680**
Total other comprehensive income for the period (net of tax)	**0**	**0**	**0**	**0**	**0**	**0**	**-1,394**	**50,003**	**0**	**0**	**0**	**48,609**	**-1,946**	**46,663**
Total comprehensive income for the period (net of tax)	**0**	**0**	**0**	**0**	**0**	**0**	**-1,394**	**50,003**	**0**	**0**	**245,844**	**294,453**	**-1,110**	**293,343**
Transactions with owners, recognised in equity														
Transfer of previous periods' profit to retained earnings	0	0	0	0	0	0	0	0	0	331,984	-331,984	0	0	0
Repurchase of treasury shares	0	-23,985	0	0	0	0	0	0	0	0	0	-23,985	0	-23,985
Formation of reserves for treasury shares	0	0	23,985	0	0	0	0	0	0	0	-23,985	0	0	0
Total transactions with owners, recognised in equity	**0**	**-23,985**	**23,985**	**0**	**0**	**0**	**0**	**0**	**0**	**331,984**	**-355,969**	**-23,985**	**0**	**-23,985**
Balance at 30 Jun 2025	**54,732**	**-187,476**	**187,476**	**105,897**	**14,990**	**30,000**	**-12,756**	**-116,698**	**1,620,098**	**570,529**	**221,859**	**2,488,651**	**18,491**	**2,507,142**

Consolidated statement of cash flows of the Krka Group

€ thousand	Jan–Jun 2026	Jan–Jun 2025
CASH FLOWS FROM OPERATING ACTIVITIES		
Net profit	**260,170**	**246,680**
Adjustments for:	**120,441**	**152,630**
– Amortisation/Depreciation	48,228	46,277
– Net foreign exchange gains and losses	8,660	35,137
– Net write-offs and allowances for inventories	9,813	9,354
– Net impairments and write-offs of receivables	130	3,106
– Investment income	-12,347	-10,139
– Investment expenses	280	10,552
– Income on financing activities	-4	-2
– Interest expense and other finance expenses	5,901	5,611
– Income tax expense	59,780	52,734
Operating profit before changes in net current assets	**380,611**	**399,310**
Change in trade receivables	-121,110	-81,892
Change in inventories	3,639	-30,940
Change in trade payables	19,709	7,214
Change in provisions	135	98
Change in deferred income	-122	-169
Change in other current liabilities	17,305	13,705
Income tax paid	-74,772	-53,408
Net cash flow from operating activities	**225,395**	**253,918**
CASH FLOWS FROM INVESTING ACTIVITIES		
Interest received	4,206	6,003
Dividends received	3	2
Proceeds from sale of property, plant and equipment	2,524	1,751
Acquisition of property, plant and equipment	-53,800	-44,970
Acquisition of intangible assets	-3,596	-2,228
Acquisition of interest in joint ventures	0	-9,234
Proceeds from non-current loans	779	3,177
Payments for non-current loans	-13,076	-2,680
Net payments for/proceeds from current loans	-16,743	1,731
Proceeds from sale of non-current investments	17	20,292
Payments for acquisition of non-current investments	-40	-25
Proceeds from sale of current investments	0	310,000
Payments for acquisition of current investments	-79,126	-316,966
Proceeds from derivatives	165	29
Payments for derivatives	-281	-2,504
Net cash flow from investing activities	**-158,968**	**-35,622**
CASH FLOWS FROM FINANCING ACTIVITIES		
Interest paid	-3,202	-3,232
Net payments for current borrowings	-3	0
Lease liabilities paid	-2,778	-2,315
Dividends and other profit shares paid	250	0
Repurchase of treasury shares	-19,007	-23,985
Net cash flow from financing activities	**-24,740**	**-29,532**
Net increase in cash and cash equivalents	**41,687**	**188,764**
Cash and cash equivalents at beginning of year	347,819	344,895
Effect of changes in foreign exchange rates on cash held	-1,418	-5,039
Closing balance of cash and cash equivalents	**388,088**	**528,620**

Segment reporting of the Krka Group

€ thousand	European Union		South-Eastern Europe		Eastern Europe		Total segment reporting		Other		Eliminations		Total	
	Jan–Jun 2026	Jan–Jun 2025	Jan–Jun 2026	Jan–Jun 2025	Jan–Jun 2026	Jan–Jun 2025	Jan–Jun 2026	Jan–Jun 2025	Jan–Jun 2026	Jan–Jun 2025	Jan–Jun 2026	Jan–Jun 2025	Jan–Jun 2026	Jan–Jun 2025
Revenue from sales to non-group customers	**583,358**	**566,143**	**68,055**	**61,907**	**405,259**	**370,407**	**1,056,672**	**998,457**	**62,673**	**50,084**			**1,119,345**	**1,048,541**
Revenue from sales to intragroup customers	**208,794**	**231,102**	**43,427**	**39,803**	**477,039**	**389,320**	**729,260**	**660,225**	**9,282**	**10,221**	**-738,542**	**-670,446**	**0**	**0**
Total revenue	**792,152**	**797,245**	**111,482**	**101,710**	**882,298**	**759,727**	**1,785,932**	**1,658,682**	**71,955**	**60,305**	**-738,542**	**-670,446**	**1,119,345**	**1,048,541**
Other operating income	2,440	2,259	66	10	359	465	2,865	2,734	8	1,390			2,873	4,124
Operating expenses	-445,356	-459,558	-43,232	-40,733	-270,458	-257,718	-759,046	-758,009	-53,947	-37,679			-812,993	-795,688
Intragroup operating expenses, including elimination of profits	-208,794	-231,102	-43,427	-39,803	-477,039	-389,320	-729,260	-660,225	-9,282	-10,221	738,542	670,446	0	0
Operating profit	**140,442**	**108,844**	**24,889**	**21,184**	**135,160**	**113,154**	**300,491**	**243,182**	**8,734**	**13,795**	**0**	**0**	**309,225**	**256,977**
Interest income	4,079	4,983	1	1	746	639	4,826	5,623	312	604			5,138	6,227
Intragroup interest income	1,199	1,190	0	0	0	0	1,199	1,190	0	0	-1,199	-1,190	0	0
Interest expense	-261	-152	-8	-5	-120	-126	-389	-283	-6	-6			-395	-289
Intragroup interest expense	-1,199	-1,190	0	0	0	0	-1,199	-1,190	0	0	1,199	1,190	0	0
Net financial result	**3,522**	**4,524**	**-174**	**-368**	**5,845**	**41,876**	**9,193**	**46,032**	**1,532**	**-3,595**			**10,725**	**42,437**
Income tax expense	-30,020	-24,500	-4,859	-4,524	-23,595	-21,661	-58,474	-50,685	-1,306	-2,049			-59,780	-52,734
Net profit	**113,944**	**88,868**	**19,856**	**16,292**	**117,410**	**133,369**	**251,210**	**238,529**	**8,960**	**8,151**	**0**	**0**	**260,170**	**246,680**
Investments	50,884	37,009	231	391	1,711	2,899	52,826	40,299	3	587			52,829	40,886
Depreciation of property, plant and equipment	28,489	28,789	1,063	1,025	11,082	9,794	40,634	39,608	1,603	1,505			42,237	41,113
Depreciation of right-of-use assets	1,965	1,652	78	67	413	312	2,456	2,031	59	43			2,515	2,074
Amortisation of intangible assets	1,978	1,898	183	158	1,176	928	3,337	2,984	139	106			3,476	3,090
	30 Jun 2026	**31 Dec 2025**	**30 Jun 2026**	**31 Dec 2025**	**30 Jun 2026**	**31 Dec 2025**	**30 Jun 2026**	**31 Dec 2025**	**30 Jun 2026**	**31 Dec 2025**	**30 Jun 2026**	**31 Dec 2025**	**30 Jun 2026**	**31 Dec 2025**
Total assets	**2,308,975**	**2,178,925**	**91,184**	**86,724**	**794,762**	**655,519**	**3,194,921**	**2,921,168**	**133,814**	**121,490**			**3,328,735**	**3,042,658**
Non-current assets exclusive of deferred tax assets	861,317	862,295	8,138	6,756	96,741	88,492	966,196	957,543	37,805	32,747			1,004,001	990,290
Total liabilities	**405,276**	**399,923**	**25,188**	**24,925**	**229,369**	**205,694**	**659,833**	**630,542**	**39,689**	**34,965**			**699,522**	**665,507**

The Krka Group reports by specific geographical segments. Revenue generated by individual segments is presented by customers' geographical location. The data are calculated based on revenue and expenses, as well as assets and liabilities directly attributable to each Krka Group market. Eliminations relate to transactions between the controlling company and its subsidiaries, as well as between subsidiaries themselves.

Notes to consolidated financial statements of the Krka Group

Costs by nature €812,993 thousand

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Cost of goods and materials	280,405	287,457	98
Cost of services	129,437	128,601	101
Employee benefits expense	343,350	308,313	111
Amortisation and depreciation	48,228	46,277	104
Net write-offs and allowances for inventories	9,813	9,354	105
Net impairments and write-offs of receivables	130	3,106	4
Other operating expenses	23,424	21,832	107
Total costs	**834,787**	**804,940**	**104**
Change in the value of inventories of finished products and work in progress	-21,794	-9,252	236
Total	**812,993**	**795,688**	**102**

Employee benefits €343,350 thousand

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Gross wages and salaries and continued pay	263,598	238,278	111
Social security contributions	20,900	15,988	131
Pension insurance contributions	36,422	33,349	109
Payroll tax	481	430	112
Post-employment benefits and other non-current employee benefits	3,588	3,654	98
Other employee benefits expense	18,361	16,614	111
Total employee benefits	**343,350**	**308,313**	**111**

Other operating expenses €23,424 thousand

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Grants and assistance for humanitarian and other purposes	1,068	967	110
Environmental protection expenditures	3,472	2,946	118
Other taxes and levies	15,840	14,223	111
Loss on sale and write-offs of property, plant and equipment and intangible assets	177	899	20
Other operating expenses	2,867	2,797	103
Total other operating expenses	**23,424**	**21,832**	**107**

Other levies include various taxes and levies on pharmaceuticals and fees paid to medical representatives in individual countries for pursuing promotional activities.

Financial income and expenses

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Net foreign exchange gains	5,631	48,117	12
Interest income	5,138	6,227	83
Derivative income	2,952	29	10,179
– Realised revenue	165	29	569
– Fair value change	2,787	0	
Income from other financial instruments	3,129	2,957	106
– Realised revenue	0	5,062	0
– Fair value change	3,129	-2,105	
Dividend income	3	2	150
Share of profit from equity-accounted investments	65	0	
Other financial income	3	2	150
Total financial income	**16,921**	**57,334**	**30**
Interest expense	-395	-289	137
– Interest paid	-14	-1	1,400
– Interest expense on lease liabilities	-381	-288	132
Derivative expenses	-281	-9,285	3
– Realised expenses	-281	-2,504	11
– Fair value change	0	-6,781	0
Other financial expenses	-5,520	-5,323	104
Total financial expenses	**-6,196**	**-14,897**	**42**
Net financial result	**10,725**	**42,437**	**25**

Income tax expense €59,780 thousand

Current income tax amounted to €70,044 thousand or 21.9% of profit before tax. Taking into account deferred tax of -€10,503 thousand and other income-based taxes of €239 thousand, the tax expensed in the income statement totalled €59,780 thousand. The effective tax rate was 18.7%.

Property, plant and equipment €822,778 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Land	66,860	66,178	101
Buildings	348,014	348,112	100
Equipment	322,561	327,022	99
Property, plant and equipment being acquired	67,573	69,733	97
Right-of-use assets	17,770	17,860	99
Total property, plant and equipment	**822,778**	**828,905**	**99**

The value of property, plant, and equipment accounted for 25% of the Krka Group balance sheet total. See the 'Investments' section in the business report for details on major investments of Krka.

Intangible assets €114,551 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Goodwill	42,644	42,644	100
Trademark	30,999	31,435	99
Concessions, trademarks and licences	27,285	16,768	163
Other intangible assets	6,101	6,709	91
– Long-term deferred operating costs	65	121	54
– Development-related projects	4,109	4,564	90
– Emission coupons	1,927	2,024	95
Intangible assets being acquired	7,522	2,231	337
Total intangible assets	**114,551**	**99,787**	**115**

Loans €155,181 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Non-current loans	**31,140**	**25,115**	**124**
– Loans to joint ventures	10,532	0	
– Loans to others	20,608	25,115	82
Current loans	**124,041**	**99,585**	**125**
– Portion of non-current loans maturing next year	15,382	12,022	128
– Loans to others	2,797	2,632	106
– Deposits granted to banks	103,000	83,001	124
– Current interest receivable	2,862	1,930	148
Total loans	**155,181**	**124,700**	**124**

Investments €361,421 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Non-current investments	**19,338**	**20,060**	**96**
– Investments at fair value through OCI (equity instruments)	19,338	20,060	96
Current investments including derivatives	**342,083**	**257,288**	**133**
– Investments at fair value through profit or loss	339,543	257,288	132
– Derivatives	2,540	0	
Total investments	**361,421**	**277,348**	**130**

Investments at fair value through OCI comprised €1,704 thousand of investments in shares and interests in companies in Slovenia (end of 2025: €1,558 thousand), and €17,634 thousand of investments in shares and interests in companies outside Slovenia (end of 2025: €18,502 thousand).

The increase in investments at fair value through profit or loss of €82,255 thousand included acquisitions of treasury bills of €79,126 thousand and treasury bill revaluation of €3,129 thousand.

Inventories €630,650 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Materials	240,440	254,813	94
Work in progress	136,046	122,076	111
Finished products	183,862	185,581	99
Merchandise	44,431	50,485	88
Advances for inventories	25,871	31,147	83
Total inventories	**630,650**	**644,102**	**98**

Trade and other receivables €758,183 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Current trade receivables	690,492	609,315	113
Current receivables due from others	67,691	24,188	280
Total receivables	**758,183**	**633,503**	**120**

Cash and cash equivalents €388,088 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Cash in hand	122	51	239
Bank balances	387,966	347,768	112
Total cash and cash equivalents	**388,088**	**347,819**	**112**

Bank balances included a deposit of €310,270 thousand with a maturity of up to 90 days (31 December 2025: €286,403 thousand).

Equity €2,629,213 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Share capital	54,732	54,732	100
Treasury shares	-244,054	-225,047	108
Reserves	277,496	249,022	111
– Reserves for treasury shares	244,054	225,047	108
– Share premium	105,897	105,897	100
– Legal reserves	14,990	14,990	100
– Statutory reserves	30,000	30,000	100
– Fair value reserve	-7,150	-6,579	109
– Translation reserve	-110,295	-120,333	92
Retained earnings	2,521,448	2,279,945	111
Total equity attributable to the holders of the controlling company	**2,609,622**	**2,358,652**	**111**
Non-controlling interests	19,591	18,499	106
Total equity	**2,629,213**	**2,377,151**	**111**

Provisions €165,135 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Non-current provisions	**137,315**	**135,188**	**102**
Provisions for lawsuits	8,112	8,245	98
Provisions for post-employment benefits	106,859	105,314	101
Provisions for other non-current employee benefits	22,062	21,010	105
Other provisions	282	619	46
Current provisions	**27,820**	**27,494**	**101**
Total provisions	**165,135**	**162,682**	**102**

Deferred income

€5,229 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Grants received from the European Regional Development Fund and the budget of the Republic of Slovenia intended for the production of pharmaceuticals in the new Notol 2 plant	494	520	95
Grants received from the budget for the Dolenjske and Šmarješke Toplice health resorts and Golf Grad Otočec	2,966	2,979	100
Grants received from the European Regional Development Fund (Farma GRS)	1,160	1,243	93
Property, plant and equipment received free of charge	7	15	47
Emission coupons	0	10	0
Subsidy for purchase of joinery	86	86	100
Subsidy for upgrading trucks	69	35	197
Subsidy for electricity production from renewable energy installations	447	463	97
Total deferred income	**5,229**	**5,351**	**98**

Trade payables

€150,667 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Current trade payables	**150,667**	**124,654**	**121**
Payables to joint ventures	31	0	
Payables to domestic suppliers	50,538	46,763	108
Payables to foreign suppliers	100,098	77,891	129
Total trade payables	**150,667**	**124,654**	**121**

Current contract liabilities

€181,375 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Refund liabilities	**173,417**	**184,479**	**94**
– Bonuses and volume rebates	171,666	182,401	94
– Rights of return	1,751	2,078	84
Contract liabilities	**7,958**	**7,505**	**106**
– Deferred income	1,207	1,212	100
– Advances from other customers	6,751	6,293	107
Total current contract liabilities	**181,375**	**191,984**	**94**

Other current liabilities

€135,604 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Payables to employees – gross salaries, other receipts and charges	120,642	105,656	114
Derivatives	0	247	0
Other	14,962	12,646	118
Total other current liabilities	**135,604**	**118,549**	**114**

Fair value

€ thousand	30 Jun 2026		31 Dec 2025	
	Carrying amount	Fair value	Carrying amount	Fair value
Non-current financial assets				
Loans	31,140		25,115	
Investments at fair value through OCI (equity instruments)	19,338	19,338	20,060	20,060
Current financial assets				
Loans	124,041		99,585	
Investments at fair value through profit or loss	339,543	339,543	257,288	257,288
Derivatives	2,540		0	
Trade receivables	690,492		609,315	
Cash and cash equivalents	388,088		347,819	
Non-current financial liabilities				
Lease liabilities	-13,868		-14,011	
Current financial liabilities				
Borrowings	0		-3	
Derivatives	0	0	-247	-247
Lease liabilities	-4,563		-4,347	
Trade payables to suppliers and joint ventures, excluding advances	-150,667		-124,654	
Contract liabilities excluding advances	-171,666		-182,401	
Other liabilities excluding amounts owed to the State, to employees, and advances	-4,301		-4,809	
Total	**1,250,117**	**358,881**	**1,028,710**	**277,101**

In terms of fair value, assets and liabilities are classified into three levels:

- Level 1 – assets at market price;
- Level 2 – assets not classified within level 1 and the value of which is determined directly or indirectly based on observable market data;
- Level 3 – assets, the value of which cannot be determined using observable market data.

Assets at fair value

€ thousand	30 Jun 2026				31 Dec 2025			
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
Assets at fair value								
Investments at fair value through OCI (equity instruments)	17,951	0	1,387	19,338	18,673	0	1,387	20,060
Investments at fair value through profit or loss	339,543	0	0	339,543	257,288	0	0	257,288
Derivatives	0	0	2,540	2,540	0	0	0	0
Total assets at fair value	**357,494**	**0**	**3,927**	**361,421**	**275,961**	**0**	**1,387**	**277,348**

CONDENSED FINANCIAL STATEMENTS OF KRKA, D. D., NOVO MESTO, WITH NOTES

Statement of financial position of Krka, d. d., Novo mesto

€ thousand	30 Jun 2026	31 Dec 2025	Index
Assets			
Property, plant and equipment	601,772	611,845	98
Intangible assets	40,123	24,363	165
Investments in subsidiaries	354,265	355,265	100
Investments in joint ventures	16,574	16,574	100
Loans	37,340	25,504	146
Investments	19,337	20,059	96
Deferred tax assets	4,199	4,347	97
Other non-current assets	676	665	102
Total non-current assets	**1,074,286**	**1,058,622**	**101**
Inventories	532,615	539,860	99
Trade receivables	719,657	560,340	128
Other receivables	20,857	11,125	187
Loans	59,802	60,509	99
Investments	342,083	257,288	133
Cash and cash equivalents	326,890	273,658	119
Total current assets	**2,001,904**	**1,702,780**	**118**
Total assets	**3,076,190**	**2,761,402**	**111**
Equity			
Share capital	54,732	54,732	100
Treasury shares	-244,054	-225,047	108
Reserves	389,621	371,177	105
Retained earnings	2,326,808	2,071,722	112
Total equity	**2,527,107**	**2,272,584**	**111**
Liabilities			
Provisions	126,687	123,912	102
Deferred income	2,261	2,363	96
Lease liabilities	6,278	6,646	94
Total non-current liabilities	**135,226**	**132,921**	**102**
Provisions	18,671	18,671	100
Trade payables	195,978	160,231	122
Borrowings	44,488	34,376	129
Lease liabilities	1,633	1,717	95
Income tax payables	27,788	26,872	103
Contract liabilities	24,104	23,772	101
Other current liabilities	101,195	90,258	112
Total current liabilities	**413,857**	**355,897**	**116**
Total liabilities	**549,083**	**488,818**	**112**
Total equity and liabilities	**3,076,190**	**2,761,402**	**111**

Income statement of Krka, d. d., Novo mesto

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Revenue	**1,064,404**	**981,047**	**108**
– Revenue from contracts with customers	1,058,606	976,715	108
– Other revenue	5,798	4,332	134
Cost of goods sold	-404,177	-402,797	100
Gross profit	**660,227**	**578,250**	**114**
Other operating income	1,336	1,148	116
Selling and distribution expenses	-185,543	-169,375	110
– Whereof net impairments and write-offs of receivables	-292	-3,296	9
R&D expenses	-98,853	-93,444	106
General and administrative expenses	-55,229	-53,651	103
Operating profit	**321,938**	**262,928**	**122**
Financial income	18,041	63,106	29
Financial expenses	-3,660	-12,246	30
Net financial result	**14,381**	**50,860**	**28**
Profit before tax	**336,319**	**313,788**	**107**
Income tax expense	-62,477	-55,927	112
Net profit	**273,842**	**257,861**	**106**
Basic earnings per share[1] (€)	**9.04**	**8.43**	**107**
Diluted earnings per share[2] (€)	**9.04**	**8.43**	**107**

[1] Net profit/Average number of shares issued in the period, excluding treasury shares
[2] All shares issued by the controlling company are ordinary shares, hence the diluted earnings per share ratio equalled basic earnings per share.

Statement of other comprehensive income of Krka, d. d., Novo mesto

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Net profit	**273,842**	**257,861**	**106**
Other comprehensive income for the period			
Other comprehensive income that will not be reclassified to profit or loss at a future date			
Change in fair value of financial assets	-721	-1,793	40
Deferred tax effect	158	394	40
Net other comprehensive income that will not be reclassified to profit or loss at a future date	**-563**	**-1,399**	**40**
Total other comprehensive income for the period (net of tax)	**-563**	**-1,399**	**40**
Total comprehensive income for the period (net of tax)	**273,279**	**256,462**	**107**

Statement of changes in equity of Krka, d. d., Novo mesto

€ thousand	Share capital	Treasury shares	Reserves: Reserves for treasury shares	Reserves: Share premium	Reserves: Legal reserves	Reserves: Statutory reserves	Reserves: Fair value reserve	Retained earnings: Other profit reserves	Retained earnings: Retained earnings from previous periods	Retained earnings: Profit for the period	Total equity
Balance at 1 Jan 2026	**54,732**	**-225,047**	**225,047**	**105,897**	**14,990**	**30,000**	**-4,757**	**1,679,151**	**58,755**	**333,816**	**2,272,584**
Net profit	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**273,842**	**273,842**
Total other comprehensive income for the period (net of tax)	**0**	**0**	**0**	**0**	**0**	**0**	**-563**	**0**	**0**	**0**	**-563**
Total comprehensive income for the period (net of tax)	**0**	**0**	**0**	**0**	**0**	**0**	**-563**	**0**	**0**	**273,842**	**273,279**
Transactions with owners, recognised in equity											
Transfer of previous periods' profit to retained earnings	0	0	0	0	0	0	0	0	333,816	-333,816	0
Repurchase of treasury shares	0	-19,007	0	0	0	0	0	0	0	0	-19,007
Formation of reserves for treasury shares	0	0	19,007	0	0	0	0	0	0	-19,007	0
Dividends paid	0	0	0	0	0	0	0	0	251	0	251
Total transactions with owners, recognised in equity	**0**	**-19,007**	**19,007**	**0**	**0**	**0**	**0**	**0**	**334,067**	**-352,823**	**-18,756**
Balance at 30 Jun 2026	**54,732**	**-244,054**	**244,054**	**105,897**	**14,990**	**30,000**	**-5,320**	**1,679,151**	**392,822**	**254,835**	**2,527,107**

€ thousand	Share capital	Treasury shares	Reserves					Retained earnings			Total equity
			Reserves for treasury shares	Share premium	Legal reserves	Statutory reserves	Fair value reserve	Other profit reserves	Retained earnings from previous periods	Profit for the period	
Balance at 1 Jan 2025	**54,732**	**-163,491**	**163,491**	**105,897**	**14,990**	**30,000**	**-9,435**	**1,620,098**	**73,879**	**296,190**	**2,186,351**
Net profit	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**257,861**	**257,861**
Total other comprehensive income for the period (net of tax)	**0**	**0**	**0**	**0**	**0**	**0**	**-1,399**	**0**	**0**	**0**	**-1,399**
Total comprehensive income for the period (net of tax)	**0**	**0**	**0**	**0**	**0**	**0**	**-1,399**	**0**	**0**	**257,861**	**256,462**
Transactions with owners, recognised in equity											
Transfer of previous periods' profit to retained earnings	0	0	0	0	0	0	0	0	296,190	-296,190	0
Repurchase of treasury shares	0	-23,985	0	0	0	0	0	0	0	0	-23,985
Formation of reserves for treasury shares	0	0	23,985	0	0	0	0	0	0	-23,985	0
Total transactions with owners, recognised in equity	**0**	**-23,985**	**23,985**	**0**	**0**	**0**	**0**	**0**	**296,190**	**-320,175**	**-23,985**
Balance at 30 Jun 2025	**54,732**	**-187,476**	**187,476**	**105,897**	**14,990**	**30,000**	**-10,834**	**1,620,098**	**370,069**	**233,876**	**2,418,828**

Statement of cash flows of Krka, d. d., Novo mesto

€ thousand	Jan–Jun 2026	Jan–Jun 2025
CASH FLOWS FROM OPERATING ACTIVITIES		
Net profit	**273,842**	**257,861**
Adjustments for:	**96,138**	**107,148**
– Amortisation/Depreciation	35,241	34,501
– Net foreign exchange gains and losses	-274	3,380
– Net write-offs and allowances for inventories	5,983	5,395
– Net impairments and write-offs of receivables	292	3,296
– Investment income	-11,120	-8,812
– Investment expenses	165	10,502
– Income on financing activities	-4	-2
– Interest expense and other finance expenses	3,378	2,961
– Income tax expense	62,477	55,927
Operating profit before changes in net current assets	**369,980**	**365,009**
Change in trade receivables	-169,352	-101,178
Change in inventories	1,262	-12,040
Change in trade payables	39,655	25,715
Change in non-current provisions	535	747
Change in deferred income	-102	-126
Change in other current liabilities	11,183	7,493
Income tax paid	-61,254	-42,036
Net cash flow from operating activities	**191,907**	**243,584**
CASH FLOWS FROM INVESTING ACTIVITIES		
Interest received	3,303	3,930
Dividends received	3	2
Proportionate profit of subsidiaries	898	1,259
Proceeds from sale of property, plant and equipment	1,762	1,050
Acquisition of property, plant and equipment	-41,938	-32,791
Acquisition of intangible assets	-3,481	-1,904
Refunds of subsequent contributions to subsidiaries	1,000	0
Acquisition of interest in joint ventures	0	-9,234
Proceeds from non-current loans	1,168	1,230
Payments for non-current loans	-12,928	-2,490
Net proceeds from/payments for current loans	1,602	-3,524
Proceeds from sale of non-current investments	12	20,271
Payments for acquisition of non-current investments	-23	-15
Proceeds from sale of current investments	0	310,000
Payments for acquisition of current investments	-79,126	-316,966
Proceeds from derivatives	165	29
Payments for derivatives	-281	-2,504
Net cash flow from investing activities	**-127,864**	**-31,657**
CASH FLOWS FROM FINANCING ACTIVITIES		
Interest paid	-801	-870
Net proceeds from/payments for current borrowings	9,907	-180
Lease liabilities paid	-1,015	-644
Dividends and other profit shares paid	250	0
Repurchase of treasury shares	-19,007	-23,985
Net cash flow from financing activities	**-10,666**	**-25,679**
Net increase in cash and cash equivalents	**53,377**	**186,248**
Cash and cash equivalents at beginning of year	273,658	238,183
Effect of changes in foreign exchange rates on cash held	-145	-784
Closing balance of cash and cash equivalents	**326,890**	**423,647**

Notes to financial statements of Krka, d. d., Novo mesto

Costs by nature €743,802 thousand

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Cost of goods and materials	278,915	276,967	101
Cost of services	182,425	172,435	106
Employee benefits expense	246,191	220,212	112
Amortisation and depreciation	35,241	34,501	102
Net write-offs and allowances for inventories	5,983	5,395	111
Net impairments and write-offs of receivables	292	3,296	9
Other operating expenses	17,266	15,685	110
Total costs	**766,313**	**728,491**	**105**
Change in the value of inventories of finished products and work in progress	-22,511	-9,224	244
Total	**743,802**	**719,267**	**103**

Employee benefits €246,191 thousand

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Gross wages and salaries and continued pay	189,004	170,338	111
Social security contributions	15,947	11,432	139
Pension insurance contributions	23,580	22,085	107
Post-employment benefits and other non-current employee benefits	3,319	3,460	96
Other employee benefits expense	14,341	12,897	111
Total employee benefits	**246,191**	**220,212**	**112**

Other operating expenses €17,266 thousand

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Grants and assistance for humanitarian and other purposes	955	889	107
Environmental protection expenditures	2,257	1,860	121
Other taxes and levies	12,139	10,210	119
Loss on sale and write-offs of property, plant and equipment and intangible assets	60	837	7
Other operating expenses	1,855	1,889	98
Total other operating expenses	**17,266**	**15,685**	**110**

Other levies include various taxes and levies on pharmaceuticals and fees paid to medical representatives in individual countries for pursuing promotional activities.

Financial income and expenses

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Net foreign exchange gains	7,295	54,553	13
Interest income	3,764	4,278	88
Derivative income	2,952	29	10,179
– Realised revenue	165	29	569
– Fair value change	2,787	0	
Income from other financial instruments	3,129	2,957	106
– Realised revenue	0	5,062	0
– Fair value change	3,129	-2,105	
Income from dividends and other profit shares	901	1,289	70
– Dividends	3	2	150
– Profits of subsidiaries	898	1,287	70
Total financial income	**18,041**	**63,106**	**29**
Interest expense	-1,025	-860	119
– Interest paid	-891	-812	110
– Interest expense on lease liabilities	-134	-48	279
Derivative expenses	-281	-9,285	3
– Realised expenses	-281	-2,504	11
– Fair value change	0	-6,781	0
Other financial expenses	-2,354	-2,101	112
Total financial expenses	**-3,660**	**-12,246**	**30**
Net financial result	**14,381**	**50,860**	**28**

Income tax expense €62,477 thousand

Current income tax amounted to €61,930 thousand or 18.4% of profit before tax. Taking into account deferred tax of €306 thousand and other income-based taxes of €241 thousand, the tax expensed in the income statement totalled €62,477 thousand. The effective tax rate was 18.6%.

Property, plant and equipment €601,772 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Land	53,757	53,092	101
Buildings	230,506	232,722	99
Equipment	255,285	260,804	98
Property, plant and equipment being acquired	54,504	56,922	96
Right-of-use assets	7,720	8,305	93
Total property, plant and equipment	**601,772**	**611,845**	**98**

The value of property, plant and equipment accounted for 20% of the Krka balance sheet total. See the 'Investments' section in the business report for details on major investments of Krka.

Intangible assets €40,123 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Concessions, trademarks and licences	26,566	15,740	169
Other intangible assets	6,088	6,672	91
– Long-term deferred operating costs	52	84	62
– Development-related projects	4,109	4,564	90
– Emission coupons	1,927	2,024	95
Intangible assets being acquired	7,469	1,951	383
Total intangible assets	**40,123**	**24,363**	**165**

Intangible assets refer to software and registration documents for new pharmaceuticals.

Loans €97,142 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Non-current loans	**37,340**	**25,504**	**146**
– Loans to subsidiaries	11,100	11,100	100
– Loans to joint ventures	10,532	0	
– Loans to others	15,708	14,404	109
Current loans	**59,802**	**60,509**	**99**
– Portion of non-current loans maturing next year	2,254	2,108	107
– Loans to subsidiaries	8,409	4,734	178
– Loans to others	210	199	106
– Deposits granted to banks	48,000	53,000	91
– Current interest receivable	929	468	199
Total loans	**97,142**	**86,013**	**113**

Investments €361,420 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Non-current investments	**19,337**	**20,059**	**96**
– Investments at fair value through OCI (equity instruments)	19,337	20,059	96
Current investments including derivatives	**342,083**	**257,288**	**133**
– Investments at fair value through profit or loss	339,543	257,288	132
– Derivatives	2,540	0	
Total investments	**361,420**	**277,347**	**130**

Investments at fair value through OCI comprised €1,703 thousand of investments in shares and interests in companies in Slovenia (end of 2025: €1,557 thousand), and €17,634 thousand of investments in shares and interests in companies outside Slovenia (end of 2025: €18,502 thousand).

The increase in investments at fair value through profit or loss of €82,255 thousand included acquisitions of treasury bills of €79,126 thousand and treasury bill revaluation of €3,129 thousand.

Inventories €532,615 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Materials	221,971	237,386	94
Work in progress	119,075	108,427	110
Finished products	118,469	110,352	107
Merchandise	47,350	52,645	90
Advances for inventories	25,750	31,050	83
Total inventories	**532,615**	**539,860**	**99**

Trade and other receivables €740,514 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Current trade receivables	719,657	560,340	128
– Receivables due from subsidiaries	454,704	313,900	145
– Receivables due from customers other than Krka Group companies	264,953	246,440	108
Current receivables due from others	20,857	11,125	187
Total receivables	**740,514**	**571,465**	**130**

Cash and cash equivalents €326,890 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Bank balances	326,890	273,658	119
Total cash and cash equivalents	**326,890**	**273,658**	**119**

Bank balances included a deposit of €304,000 thousand with a maturity of up to 90 days (31 December 2025: €246,915 thousand).

Equity €2,527,107 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Share capital	54,732	54,732	100
Treasury shares	-244,054	-225,047	108
Reserves:	389,621	371,177	105
– Reserves for treasury shares	244,054	225,047	108
– Share premium	105,897	105,897	100
– Legal reserves	14,990	14,990	100
– Statutory reserves	30,000	30,000	100
– Fair value reserve	-5,320	-4,757	112
Retained earnings	2,326,808	2,071,722	112
Total equity	**2,527,107**	**2,272,584**	**111**

Provisions €145,358 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Non-current provisions	**126,687**	**123,912**	**102**
Provisions for lawsuits	7,400	7,400	100
Provisions for post-employment benefits	98,350	96,588	102
Provisions for other non-current employee benefits	20,937	19,924	105
Current provisions	**18,671**	**18,671**	**100**
Total provisions	**145,358**	**142,583**	**102**

Deferred income €2,261 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Grants received from the European Regional Development Fund and the budget of the Republic of Slovenia intended for the production of pharmaceuticals in the new Notol 2 plant	494	520	95
Property, plant and equipment received free of charge	5	6	83
Emission coupons	0	10	0
Subsidy for purchase of joinery	86	86	100
Grants received from the European Regional Development Fund (Farma GRS)	1,160	1,243	93
Subsidy for upgrading trucks	69	35	197
Subsidy for electricity production from renewable energy installations	447	463	97
Total deferred income	**2,261**	**2,363**	**96**

Trade payables €195,978 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Current trade payables	**195,978**	**160,231**	**122**
Payables to subsidiaries	69,850	63,520	110
Payables to joint ventures	31	0	
Payables to domestic suppliers	46,206	42,327	109
Payables to foreign suppliers	79,891	54,384	147
Total trade payables	**195,978**	**160,231**	**122**

Borrowings €44,488 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Current borrowings	**44,488**	**34,376**	**129**
– Borrowings from subsidiaries	44,187	34,278	129
– Current interest payable	301	98	307
Total borrowings	**44,488**	**34,376**	**129**

Current contract liabilities €24,104 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Refund liabilities	**19,666**	**19,373**	**102**
– Bonuses and volume rebates	19,666	19,373	102
Contract liabilities	**4,438**	**4,399**	**101**
– Advances from Krka Group customers	0	342	0
– Advances from other customers	4,438	4,057	109
Total current contract liabilities	**24,104**	**23,772**	**101**

Other current liabilities €101,195 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Payables to employees – gross salaries, other receipts and charges	98,480	88,225	112
Derivatives	0	247	0
Other	2,715	1,786	152
Total other current liabilities	**101,195**	**90,258**	**112**

Contingent liabilities and commitments €26,188 thousand

€ thousand	30 Jun 2026	31 Dec 2025	Index
Guarantees issued	17,190	25,192	68
Contingent liabilities	8,149	7,858	104
Other	849	853	100
Total contingent liabilities	**26,188**	**33,903**	**77**

Fair value

€ thousand	30 Jun 2026		31 Dec 2025	
	Carrying amount	Fair value	Carrying amount	Fair value
Non-current financial assets				
Loans	37,340		25,504	
Investments at fair value through OCI (equity instruments)	19,337	19,337	20,059	20,059
Current financial assets				
Loans	59,802		60,509	
Investments at fair value through profit or loss	339,543	339,543	257,288	257,288
Derivatives	2,540	2,540	0	0
Trade receivables	719,657		560,340	
Cash and cash equivalents	326,890		273,658	
Non-current financial liabilities				
Lease liabilities	-6,278		-6,646	
Current financial liabilities				
Borrowings	-44,488		-34,376	
Derivatives	0	0	-247	-247
Lease liabilities	-1,633		-1,717	
Trade payables to suppliers, subsidiaries and joint ventures, excluding advances	-195,978		-160,231	
Contract liabilities excluding advances	-19,666		-19,373	
Other liabilities excluding amounts owed to the State, to employees, and advances	-585		-1,046	
Total	**1,236,481**	**361,420**	**973,722**	**277,100**

In terms of fair value, assets and liabilities are classified into three levels:

- Level 1 – assets at market price;
- Level 2 – assets not classified within level 1 and the value of which is determined directly or indirectly based on observable market data;
- Level 3 – assets, the value of which cannot be determined using observable market data.

Assets at fair value

€ thousand	30 Jun 2026				31 Dec 2025			
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
Assets at fair value								
Investments at fair value through OCI (equity instruments)	17,951	0	1,386	19,337	18,673	0	1,386	20,059
Investments at fair value through profit or loss	339,543	0	0	339,543	257,288	0	0	257,288
Derivatives	0	0	2,540	2,540	0	0	0	0
Total assets at fair value	**357,494**	**0**	**3,926**	**361,420**	**275,961**	**0**	**1,386**	**277,347**

STATEMENT OF COMPLIANCE

The Management Board of Krka, d. d., Novo mesto hereby states that the condensed financial statements of Krka and the condensed consolidated financial statements of the Krka Group for the period ended 30 June 2026 have been prepared so as to provide a true and fair view of the financial position and operating results of the Krka Group and Krka. The condensed financial statements for the first half of 2026 have been prepared using the same accounting policies as for the 2025 annual financial statements of the Krka Group and Krka.

The condensed financial statements for the period ended 30 June 2026 have been prepared pursuant to *IAS 34 – Interim Financial Reporting* and have to be read in conjunction with the annual financial statements prepared for the financial year ended 31 December 2025.

The Management Board is responsible for taking the measures required to preserve the assets of the Krka Group and Krka, and to prevent and detect fraud and other forms of misconduct.

The Management Board states that all transactions between Krka Group subsidiaries have been executed according to the concluded purchase contracts, using market prices of products and services. No significant business transactions were concluded with other related parties.

Novo mesto, 14 July 2026

Jože Colarič
President of the Management Board and CEO

Dr Aleš Rotar
Member of the Management Board

Dr Vinko Zupančič
Member of the Management Board

David Bratož
Member of the Management Board

Milena Kastelic
Member of the Management Board – Worker Director